Immuneering Corporation
- IMRX
- NASDAQ
- Biotechnology
- Oncology Drugs
- MEK Inhibitor
- Neuroscience Therapeutics
$3.58
Today −0.28%Quote Oct 19, 2026, 03:24 PM UTC
−19.51%over the last month
Max drawdown −25.8%From 1-month high −22.1%3 months −16.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$231.6M
Quote Oct 19
Next earnings
Nov 11
Expected, not confirmed
Analyst target
$15.50
+333.0% from here
Floor
$3.37
6.0% below price
Where the price sits
11 analysts
Analyst range, low to high
$14.00$17.00
- Price $3.58
- Resistance $3.65
- Consensus $15.50
The price is right under resistance. Analysts' average target sits about 333% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IMRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
57
Founded
2008